Investigational antiviral pritelivir demonstrates efficacy and improved tolerability over current treatments for refractory HSV in high-risk patients.
Clinical Trials Arena on MSN
AiCuris reports positive Phase III pritelivir results for HSV patients
The trial enrolled and treated 101 immunocompromised patients with refractory or resistant HSV infection.
Julia Ries Wexler is a writer focusing on all things health and wellness. She has over 10 years of experience in health journalism, and though she has written about pretty much every health topic ...
This Q&A with George Sawaya, MD, explores new cervical cancer screening guidelines issued in January 2026, which recommend at ...
The cause of type 1 diabetes remains unknown and is a central focus of Boston College Assistant Professor of Biology Emrah Altindis and others in his field hoping to find new ways to help 1.6 million ...
The study highlights a presymptomatic phase in type 1 diabetes progression, using immune niches to track immune changes ...
Researchers at the Johns Hopkins Kimmel Cancer Center and its Bloomberg~Kimmel Institute for Cancer Immunotherapy have ...
About Haw Par Corp. Ltd. Haw Par Corp. Ltd. is a holding company, which engages in manufacturing, marketing, and trading of healthcare products. It operates through the following segments: Healthcare, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results